Cellectis Hit With New Genome Engineering IP Suits

Law360, New York (February 21, 2012, 4:53 PM EST) -- Precision BioSciences Inc. wasted no time firing off the latest salvo in its legal battle with rival Cellectis SA, filing two suits in North Carolina accusing France-based Cellectis of infringing genome engineering technology patents issued on Tuesday.

Each of Precision BioSciences' complaints asserted a patent just issued by the U.S. Patent and Trademark Office. Both patents relate to Prescision BioSciences' “directed nuclease editor” technology, which allows the production of genome-editing enzymes that insert, remove, modify and regulate genes in mammalian and plant cells, the plaintiff said....
To view the full article, register now.